RETA 5mg

Description

RETA 5mg

Retatrutide (LY-3437943) is an investigational peptide for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. This complex approach is designed to manage blood sugar levels and aid weight loss more effectively than drugs that act on a single receptor.

The mechanism of action of retatrutide involves several key pathways. First, GLP-1, a hormone produced after a meal, stimulates insulin secretion from the pancreas, which is key to regulating blood sugar levels and affecting weight. It slows gastric emptying, making individuals feel full longer, and reduces appetite by acting on hunger centers in the brain. Second, GIP, another incretin hormone similar to GLP-1, also promotes insulin release after meals, contributing to slower gastric emptying and reduced appetite. Finally, glucagon, produced in the pancreas, helps regulate blood glucose levels by converting stored glycogen into glucose when levels drop, which can help with weight management by targeting fat stores for energy.

RETA 5mg: Retatrutide stands out because of its triple agonist nature, promising greater efficacy in weight reduction and diabetes management compared to dual or single agonists. Clinical trials have shown impressive weight loss results, suggesting that retatrutide could be a significant advance in the treatment of obesity and type 2 diabetes【28†source】【29†source】【30†source】.

More detailed information can be found at the following sources: betterweighmedical.com, Wikipedia and valhallavitality.com.

The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.